Summary of the National Advisory Committee on Immunization (NACI) Rapid Response-Interim guidance on the use of Imvamune in the context of monkeypox outbreaks in Canada
CONCLUSION: NACI has rapidly developed guidance on the use of Imvamune in Canada in the context of many uncertainties. Recommendations may be revisited as new evidence emerges.PMID:37426289 | PMC:PMC10324881 | DOI:10.14745/ccdr.v48i78a09 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - July 10, 2023 Category: Infectious Diseases Authors: April Killikelly Nicholas Brousseau Source Type: research
Summary of the National Advisory Committee on Immunization (NACI) Rapid Response-Interim guidance on the use of Imvamune in the context of monkeypox outbreaks in Canada
CONCLUSION: NACI has rapidly developed guidance on the use of Imvamune in Canada in the context of many uncertainties. Recommendations may be revisited as new evidence emerges.PMID:37426289 | PMC:PMC10324881 | DOI:10.14745/ccdr.v48i78a09 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - July 10, 2023 Category: Infectious Diseases Authors: April Killikelly Nicholas Brousseau Source Type: research
Summary of the National Advisory Committee on Immunization (NACI) Rapid Response-Interim guidance on the use of Imvamune in the context of monkeypox outbreaks in Canada
CONCLUSION: NACI has rapidly developed guidance on the use of Imvamune in Canada in the context of many uncertainties. Recommendations may be revisited as new evidence emerges.PMID:37426289 | PMC:PMC10324881 | DOI:10.14745/ccdr.v48i78a09 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - July 10, 2023 Category: Infectious Diseases Authors: April Killikelly Nicholas Brousseau Source Type: research
Summary of the National Advisory Committee on Immunization (NACI) Rapid Response-Interim guidance on the use of Imvamune in the context of monkeypox outbreaks in Canada
CONCLUSION: NACI has rapidly developed guidance on the use of Imvamune in Canada in the context of many uncertainties. Recommendations may be revisited as new evidence emerges.PMID:37426289 | PMC:PMC10324881 | DOI:10.14745/ccdr.v48i78a09 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - July 10, 2023 Category: Infectious Diseases Authors: April Killikelly Nicholas Brousseau Source Type: research
Summary of the National Advisory Committee on Immunization (NACI) Rapid Response-Interim guidance on the use of Imvamune in the context of monkeypox outbreaks in Canada
CONCLUSION: NACI has rapidly developed guidance on the use of Imvamune in Canada in the context of many uncertainties. Recommendations may be revisited as new evidence emerges.PMID:37426289 | PMC:PMC10324881 | DOI:10.14745/ccdr.v48i78a09 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - July 10, 2023 Category: Infectious Diseases Authors: April Killikelly Nicholas Brousseau Source Type: research
Summary of the National Advisory Committee on Immunization (NACI) Rapid Response-Interim guidance on the use of Imvamune in the context of monkeypox outbreaks in Canada
CONCLUSION: NACI has rapidly developed guidance on the use of Imvamune in Canada in the context of many uncertainties. Recommendations may be revisited as new evidence emerges.PMID:37426289 | PMC:PMC10324881 | DOI:10.14745/ccdr.v48i78a09 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - July 10, 2023 Category: Infectious Diseases Authors: April Killikelly Nicholas Brousseau Source Type: research
Summary of the National Advisory Committee on Immunization (NACI) Rapid Response-Interim guidance on the use of Imvamune in the context of monkeypox outbreaks in Canada
CONCLUSION: NACI has rapidly developed guidance on the use of Imvamune in Canada in the context of many uncertainties. Recommendations may be revisited as new evidence emerges.PMID:37426289 | PMC:PMC10324881 | DOI:10.14745/ccdr.v48i78a09 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - July 10, 2023 Category: Infectious Diseases Authors: April Killikelly Nicholas Brousseau Source Type: research
Summary of the National Advisory Committee on Immunization (NACI) Rapid Response-Interim guidance on the use of Imvamune in the context of monkeypox outbreaks in Canada
CONCLUSION: NACI has rapidly developed guidance on the use of Imvamune in Canada in the context of many uncertainties. Recommendations may be revisited as new evidence emerges.PMID:37426289 | PMC:PMC10324881 | DOI:10.14745/ccdr.v48i78a09 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - July 10, 2023 Category: Infectious Diseases Authors: April Killikelly Nicholas Brousseau Source Type: research
Summary of the National Advisory Committee on Immunization (NACI) Rapid Response-Interim guidance on the use of Imvamune in the context of monkeypox outbreaks in Canada
CONCLUSION: NACI has rapidly developed guidance on the use of Imvamune in Canada in the context of many uncertainties. Recommendations may be revisited as new evidence emerges.PMID:37426289 | PMC:PMC10324881 | DOI:10.14745/ccdr.v48i78a09 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - July 10, 2023 Category: Infectious Diseases Authors: April Killikelly Nicholas Brousseau Source Type: research
Summary of the National Advisory Committee on Immunization (NACI) Rapid Response-Interim guidance on the use of Imvamune in the context of monkeypox outbreaks in Canada
CONCLUSION: NACI has rapidly developed guidance on the use of Imvamune in Canada in the context of many uncertainties. Recommendations may be revisited as new evidence emerges.PMID:37426289 | PMC:PMC10324881 | DOI:10.14745/ccdr.v48i78a09 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - July 10, 2023 Category: Infectious Diseases Authors: April Killikelly Nicholas Brousseau Source Type: research
Summary of the National Advisory Committee on Immunization (NACI) Rapid Response-Interim guidance on the use of Imvamune in the context of monkeypox outbreaks in Canada
CONCLUSION: NACI has rapidly developed guidance on the use of Imvamune in Canada in the context of many uncertainties. Recommendations may be revisited as new evidence emerges.PMID:37426289 | PMC:PMC10324881 | DOI:10.14745/ccdr.v48i78a09 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - July 10, 2023 Category: Infectious Diseases Authors: April Killikelly Nicholas Brousseau Source Type: research
Summary of the National Advisory Committee on Immunization (NACI) Rapid Response-Interim guidance on the use of Imvamune in the context of monkeypox outbreaks in Canada
CONCLUSION: NACI has rapidly developed guidance on the use of Imvamune in Canada in the context of many uncertainties. Recommendations may be revisited as new evidence emerges.PMID:37426289 | PMC:PMC10324881 | DOI:10.14745/ccdr.v48i78a09 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - July 10, 2023 Category: Infectious Diseases Authors: April Killikelly Nicholas Brousseau Source Type: research
Summary of the National Advisory Committee on Immunization (NACI) Rapid Response-Interim guidance on the use of Imvamune in the context of monkeypox outbreaks in Canada
CONCLUSION: NACI has rapidly developed guidance on the use of Imvamune in Canada in the context of many uncertainties. Recommendations may be revisited as new evidence emerges.PMID:37426289 | PMC:PMC10324881 | DOI:10.14745/ccdr.v48i78a09 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - July 10, 2023 Category: Infectious Diseases Authors: April Killikelly Nicholas Brousseau Source Type: research
Summary of the National Advisory Committee on Immunization (NACI) Rapid Response-Interim guidance on the use of Imvamune in the context of monkeypox outbreaks in Canada
CONCLUSION: NACI has rapidly developed guidance on the use of Imvamune in Canada in the context of many uncertainties. Recommendations may be revisited as new evidence emerges.PMID:37426289 | PMC:PMC10324881 | DOI:10.14745/ccdr.v48i78a09 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - July 10, 2023 Category: Infectious Diseases Authors: April Killikelly Nicholas Brousseau Source Type: research
Summary of the National Advisory Committee on Immunization (NACI) Rapid Response-Interim guidance on the use of Imvamune in the context of monkeypox outbreaks in Canada
CONCLUSION: NACI has rapidly developed guidance on the use of Imvamune in Canada in the context of many uncertainties. Recommendations may be revisited as new evidence emerges.PMID:37426289 | PMC:PMC10324881 | DOI:10.14745/ccdr.v48i78a09 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - July 10, 2023 Category: Infectious Diseases Authors: April Killikelly Nicholas Brousseau Source Type: research
